HSPB1 and breast carcinoma: Our results indicated that erastin (an inducer of ferroptosis) treatment led to increased mRNA and protein levels of HSPB1 in a dose-dependent manner in breast cancer cells (Supplementary Fig. S5A), which is consistent with the observations in other cancer cells [28].